Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
Editorials
You have accessRestricted Access

Calciotropic Hormones and Arterial Physiology: “D”-lightful Insights

Dwight A. Towler
JASN February 2007, 18 (2) 369-373; DOI: https://doi.org/10.1681/ASN.2006121367
Dwight A. Towler
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Vascular calcification increasingly afflicts our aging and dysmetabolic population (1). In the past decade, vascular calcification has emerged as an actively regulated form of calcified tissue metabolism, resembling mineralization of endochondral and membranous bone (1). Demer and colleagues (2) were the first to provide molecular insights into disease pathobiology. In 1993, they identified expression of the powerful bone morphogen, BMP2, in calcium-laden type Vb atherosclerotic plaques. Detailed studies have confirmed contributions of osteogenic BMP2 and Wnt signaling cascades not only in atherosclerotic disease (2) but also during medial artery calcification of diabetes (3) and calcific aortic stenosis (4). Executive cell types that are familiar to bone biologists are seen in calcifying macrovascular specimens, controlling calcified matrix remodeling via paracrine signals that include osteopontin, matrix Gla protein, and inorganic pyrophosphate (1,3,5). Ectopic skeletal morphogens divert aortic mesoangioblasts, mural pericytes, and valve myofibroblasts to osteogenic fates (1,3,6). Ectopic vascular expression of pro-osteogenic morphogens is entrained to physiologic stimuli that promote calcification (1,3). Inflammation, mechanical shear, oxidative stress, hyperphosphatemia, and elastinolysis provide stimuli that promote osteogenic matrix remodeling and compromise vascular defenses that limit calcium deposition (1,3).

In ESRD, a “perfect storm” of metabolic, mechanical, and inflammatory insults challenges vascular health, leading to cardiovascular mortality rates that approach 20% per annum (7). Perturbations in parathyroid hormone (PTH) production that compromise normal bone formation increase the risk for vascular calcium load (8,9). Indeed, in patients stage 5 chronic kidney disease, low-turnover osteoporosis with inappropriately normal PTH levels is a strong risk factor for vascular calcium accumulation (9). Vascular calcification contributes to vascular stiffening—abnormal aortofemoral Windkessel physiology that generates systolic hypertension, increases myocardial workload, and compromises distal tissue perfusion (10).

In this issue of JASN, London et al. (11) again advance our understanding of human arterial physiology and calciotropic hormones, highlighting the importance of adequate vitamin D nutrition to maintenance of vascular structure and function in ESRD (8). As expected (10), age and hypertension strongly contribute to risk for reduced arterial compliance, evidenced by reduced brachial artery (BA) distensibility, increased aortic pulse wave velocity (PWV), and diminished flow-mediated dilation (FMD). As a sensitive index of perturbed intimal-medial signaling, reduced FMD identifies and confirms dysfunction in arterial physiology (10). The BA distensibility relationship also is important; this assessment of arterial compliance is not altered significantly by blood’s rheologic properties and, like PWV, quantifies how vascular material and geometric properties integrate to determine arterial stiffness (12,13). In ESRD, therefore, aberrancies in endothelial-medial signaling (FMD) and integrated arterial mechanical properties (PWV, BA) coexist. It is intriguing that vitamin D nutritional status, reflected by serum 25-hydroxyvitamin D (25-OHD) levels, provided substantial additional information (11). Even after accounting for the protean influences of age and BP, approximately 20% of the total variance in arterial compliance and approximately 30% of FMD response was related to the prevailing vitamin D nutritional status—positively correlated with healthy endothelial and arterial mechanical physiology (11).

What mechanisms might mediate beneficial actions of vitamin D on arterial physiology? The answer is not straightforward because of (1) the individual contributions of wall thickness, matrix composition, and neuroendocrine control of vascular smooth muscle cell (VSMC) contractility that determine net vascular compliance (13); (2) the biphasic effects of vitamin D “nutrition versus toxicity” on cardiovascular health (14–16); and (3) the differential actions—direct (endothelial, VSMC) versus indirect (endocrine, immunomodulatory)—that mediate vitamin D’s vasculotropic actions (14). In VSMC, cell-autonomous activation of the vitamin D receptor (VDR) is pro-calcific and therefore deleterious to vascular compliance (17,18). In vitro, the potent VDR agonist calcitriol (1,25-dihydroxyvitamin D3 [1,25(OH)2D3]) promotes VSMC calcification in part via PTH-related protein (PTHrP) signals that limit alkaline phosphatase induction (17,18) and thereby collapse the paracrine inorganic pyrophosphate mineralization defense mechanism (5) (Figure 1). Calcitriol promotes medial artery calcification in vivo (19); whether this requires suppression of vascular PTHrP is unknown. Moreover, toxic levels of vitamin D and calcitriol elevate serum calcium and phosphate in vivo (20)—potent stimuli for VSMC production of pro-calcific matrix vesicles (21,22).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Working model outlining of biphasic actions of vitamin D on vascular compliance. Nutritional vitamin D plays an important role in limiting renin-angiotensin-aldosterone axis–and cytokine-dependent mural inflammation. Vitamin D toxicity exerts both direct and indirect actions that enhance arterial calcification. ALP, alkaline phosphatase; 1,25(OH)2D, 1,25-dihydroxyvitamin D; 25-OHD, 25-hydroxyvitamin D; PTHrP, parathyroid hormone–related protein; VSMC, vascular smooth muscle cell.

How, then, might adequate vitamin D nutrition improve arterial physiology? From the traditional endocrine viewpoint, this might reflect amelioration of secondary hyperparathyroidism; integrated circadian production of PTH may be lower with improved vitamin D nutrition. The PTH/PTHrP receptor is functionally active on both endothelium and VSMC (23). Whereas acute PTH administration is vasodilatory (24), the chronically elevated PTH profile of primary and secondary hyperparathyroidism promotes hypertension (25,26). In patients with primary hyperparathyroidism, FMD is impaired but improves after surgical therapy (25,26). However, the few well-done studies indicate that hyperparathyroidism per se does not alter arterial PWV (again, index of material and geometric properties) (25,26). Therefore, in ESRD, the concomitant deficiencies in endothelial and integrated mechanical properties that are associated with vitamin D deficiency probably are not due simply to undetected, exaggerated hyperparathyroidism.

Could adequate vitamin D nutrition, by maintaining normal bone formation and skeletal mineralization (27,28), reduce vascular calcification and vascular stiffness? This is an attractive hypothesis, based on London’s previous study that demonstrated that low rates of bone formation are inversely related to the extent of arterial calcium load (9). In this study, however, no significant connection could be drawn between vitamin D nutritional status and clinical extent of calcific vasculopathy—even though arterial compliance was reduced significantly (11). This may relate to limitations in the available method used to quantify vascular calcium deposition. London’s method implements nonparametric scoring of the anatomic extent of arterial calcification, without quantifying mineral mass. In the slightly larger study mentioned, this method was capable of establishing inverse relationships between osteoblast-dependent bone formation and arterial calcification (9). However, other specialized methods—such as phantom-calibrated arterial mineral mass measurements using summed computed tomography (CT) numbers from thresholded multidetector CT scans—can be used to robustly quantify calcium content in any arterial segment (29,30). Mineral mass measurement has advantages in that it is less biased (29,30) and is a continuous variable (29), like measures of vascular compliance. Demer unambiguously demonstrated that arterial calcification does contribute to vessel wall stiffness on direct assessment of balloon catheter pressure-volume relationships (31). Therefore, after adjustment for age, the present study may have been inadequately powered to identify relationships between 25-OHD status and arterial calcium load with the available noninvasive metrics and appropriately conservative nonparametric statistical testing; the P value for the nonsignificant trend was 0.15 (11).

It remains probable, however, that effects of vitamin D insufficiency/deficiency on vascular stiffness are partially independent of vascular calcium load. It is intriguing to speculate that 25-OHD–dependent changes in the renin-angiotensin-aldosterone axis (32) may mediate these effects, independent of changes in BP (Figure 1). Although many patients studied were treated with angiotensin receptor blockade (ARB), these drugs were discontinued 10 d before arterial measurements. In addition to exhibiting pressor actions, angiotensin II (AngII) drives adventitial oxidative stress, cardiovascular fibrosis, and outward arterial remodeling. As robustly demonstrated by Rey and Pagano (33), AngII circumferentially activates Nox2-based arterial superoxide production in adventitial myofibroblasts. Along with medial thickening and fibrosis, an AngII-dependent adventitial-to-medial superoxide gradient antagonizes vasodilatory intimal-to-medial nitric oxide signals via chemical nullification that forms peroxynitrite (33). Adventitial inflammation also may be enhanced with vitamin D insufficiency. Vitamin D is immunomodulatory by enhancing the anti-inflammatory IL-10–to–IL-12 ratio (34). Inflammatory cytokine profiles are improved significantly in patients who have heart failure and receive supplementation with vitamin D (35). Moreover, in patients without ESRD, atherosclerotic peripheral vascular disease is associated with vitamin D deficiency (36). Therefore, vascular insult that arises from vitamin D insufficiency/deficiency may reflect exaggerated arterial oxidative stress and mural inflammation.

At this point, I caution against drawing too many conclusions on the basis of serum calcitriol levels and the full acceptance 1,25(OH)2D3 levels as an index of “hormonal” status (11). In the absence of ESRD, serum 1,25(OH)2D3 levels most often reflect responses to PTH (14) (notable exceptions exist in granulomatous disease, lymphoma, and calcitriol intoxication). In the presence of documented vitamin D deficiency with intact renal parenchyma, serum 1,25(OH)2D3 levels are related inversely with serum 25-OHD (37); 1,25(OH)2D3 levels are elevated as a result of secondary hyperparathyroidism that drives renal 1-α hydroxylation of the measurably reduced but marginally available serum 25-OHD (37). In immobilized patients with intact renal function, uncoupling of bone resorption from bone formation elevates serum calcium levels, with suppression of PTH production and secondary decreases in 1,25(OH)2D3 levels (38). However, as shown (11), in the presence of ESRD—the absence of intact renal parenchyma—serum 1,25(OH)2D3 levels directly correlate with serum 25-OHD via nonrenal 1-α hydroxylation. In London’s study (11), patients were naíve to treatment with vitamin D agonists; some contribution from calcitriol treatment of secondary hyperparathyroidism is anticipated in many patient populations. An emerging endocrine concept emphasizes that 25-OHD is a bioactive precursor for more potent VDR agonist production within the parenchyma of multiple, nonrenal target tissues, including bone (39). This is akin to testosterone as the bioactive precursor for dihydrotestosterone and estradiol in target tissues. For 25-OHD, the inflamed endothelium (40) and activated cells of the monocyte/macrophage lineage (41) are the most studied nonrenal targets for 1,25(OH)2D3 synthesis (39). The regulated contributions of these nonrenal sources to serum 1,25(OH)2D3 levels and vitamin D signaling in vascular health are not known.

Much work remains to be done. Preclinical models should be studied for consequences of vitamin D deficiency on vascular inflammation, matrix remodeling, and arterial oxidative stress—and the contributions of the renin-angiotensin-aldosterone axis to the beneficial vascular effects of adequate vitamin D nutrition. Histomorphometric and biochemical techniques that spatially resolve arterial tunic inflammation and oxidative stress (42) should be used to assess vascular effects of vitamin D insufficiency. Moreover, Cre-Lox technology (43) could be applied to evaluate how cell-autonomous VDR signaling in VSMC, macrophages, T cells, and endothelial cells contributes to vascular physiology and pathobiology in murine models. As done with selective estrogen receptor modulators, novel VDR ligands should be evaluated for “modulator” activity—the ability to function as agonists in some tissues but antagonists in others—and encompass the arterial vasculature as a relevant target tissue. In humans, the ability of ergocalciferol or cholecalciferol to improve arterial compliance should be tested—stratified for the presence or absence of vitamin D analog therapy for secondary hyperparathyroidism. Ultrasound assessment of intimal-medial wall thickness should be assessed concomitantly; this geometric property also worsens vascular stiffness independent of vessel material properties (13). These longitudinal studies could be enhanced significantly by quantitative measures of arterial calcium mass using multidetector CT; such a method would quantify better the extent to which changes in vascular calcium metabolism may contribute to vitamin D nutritional regulation of arterial compliance. All in all, this important article significantly extends London’s elegant studies (see reference [8] for review)—the seminal body of work that establishes how calciotropic hormones are intimately related to impaired arterial physiology and cardiovascular mortality of ESRD. Assiduous attention and implementation of these lessons in vascular endocrinology will be of tremendous benefit to our patients.

Disclosures

D.A.T. serves as a consultant for the National Institutes of Health, Eli Lilly, and Novartis and is a former employee of Merck and Co.

Acknowledgments

D.A.T. is supported by grants from the National Institutes of Health (HL69229, HL81138, and AR43731), the American Diabetes Association, and the Barnes-Jewish Hospital Foundation.

Footnotes

  • Published online ahead of print. Publication date available at www.jasn.org.

  • See the related article, “Mineral Metabolism and Arterial Functions in End-Stage Renal Disease: Potential Role of 25-Hydroxyvitamin D Deficiency,” on pages 613–620.

  • © 2007 American Society of Nephrology

References

  1. ↵
    Abedin M, Tintut Y, Demer LL: Vascular calcification: Mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol 24 : 1161 –1170, 2004
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Bostrom K, Watson KE, Horn S, Wortham C, Herman IM, Demer LL: Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest 91 : 1800 –1809, 1993
    OpenUrlCrossRefPubMed
  3. ↵
    Shao JS, Cai J, Towler DA: Molecular mechanisms of vascular calcification: Lessons learned from the aorta. Arterioscler Thromb Vasc Biol 26 : 1423 –1430, 2006
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Caira FC, Stock SR, Gleason TG, McGee EC, Huang J, Bonow RO, Spelsberg TC, McCarthy PM, Rahimtoola SH, Rajamannan NM: Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J Am Coll Cardiol 47 : 1707 –1712, 2006
    OpenUrlCrossRefPubMed
  5. ↵
    Towler DA: Inorganic pyrophosphate: A paracrine regulator of vascular calcification and smooth muscle phenotype. Arterioscler Thromb Vasc Biol 25 : 651 –654, 2005
    OpenUrlFREE Full Text
  6. ↵
    Collett GD, Canfield AE: Angiogenesis and pericytes in the initiation of ectopic calcification. Circ Res 96 : 930 –938, 2005
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Moe SM, Chen NX: Pathophysiology of vascular calcification in chronic kidney disease. Circ Res 95 : 560 –567, 2004
    OpenUrlAbstract/FREE Full Text
  8. ↵
    London GM, Marchais SJ, Guerin AP, Metivier F: Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia. Curr Opin Nephrol Hypertens 14 : 525 –531, 2005
    OpenUrlCrossRefPubMed
  9. ↵
    London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, de Vernejoul MC: Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 15 : 1943 –1951, 2004
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Safar ME, Boudier HS: Vascular development, pulse pressure, and the mechanisms of hypertension. Hypertension 46 : 205 –209, 2005
    OpenUrlAbstract/FREE Full Text
  11. ↵
    London GM, Guerin AP, Verbeke FH, Pannier B, Boutouyrie P, Marchais SJ, Metivier F: Mineral metabolism and arterial functions in end-stage renal disease: Potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 18 : 613 –620, 2007
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Niederhoffer N, Lartaud-Idjouadiene I, Giummelly P, Duvivier C, Peslin R, Atkinson J: Calcification of medial elastic fibers and aortic elasticity. Hypertension 29 : 999 –1006, 1997
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Blacher J, Safar ME: Large-artery stiffness, hypertension and cardiovascular risk in older patients. Nat Clin Pract Cardiovasc Med 2 : 450 –455, 2005
    OpenUrlCrossRefPubMed
  14. ↵
    Feldman D, Glorieux FH, Pike JW: Vitamin D, 2nd Ed., Amsterdam, Elsevier Academic Press, 2005
  15. Holick MF: Sunlight and vitamin D: Both good for cardiovascular health. J Gen Intern Med 17 : 733 –735, 2002
    OpenUrlCrossRefPubMed
  16. ↵
    Haffner D, Hocher B, Muller D, Simon K, Konig K, Richter CM, Eggert B, Schwarz J, Godes M, Nissel R, Querfeld U: Systemic cardiovascular disease in uremic rats induced by 1,25(OH)2D3. J Hypertens 23 : 1067 –1075, 2005
    OpenUrlCrossRefPubMed
  17. ↵
    Jono S, Nishizawa Y, Shioi A, Morii H: 1,25-Dihydroxyvitamin D3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide. Circulation 98 : 1302 –1306, 1998
  18. ↵
    Jono S, Nishizawa Y, Shioi A, Morii H: Parathyroid hormone-related peptide as a local regulator of vascular calcification. Its inhibitory action on in vitro calcification by bovine vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 17 : 1135 –1142, 1997
    OpenUrlAbstract/FREE Full Text
  19. ↵
    Henley C, Colloton M, Cattley RC, Shatzen E, Towler DA, Lacey D, Martin D: 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism. Nephrol Dial Transplant 20 : 1370 –1377, 2005
    OpenUrlCrossRefPubMed
  20. ↵
    Price PA, Faus SA, Williamson MK: Warfarin-induced artery calcification is accelerated by growth and vitamin D. Arterioscler Thromb Vasc Biol 20 : 317 –327, 2000
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Reynolds JL, Joannides AJ, Skepper JN, McNair R, Schurgers LJ, Proudfoot D, Jahnen-Dechent W, Weissberg PL, Shanahan CM: Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: A potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 15 : 2857 –2867, 2004
    OpenUrlAbstract/FREE Full Text
  22. ↵
    Reynolds JL, Skepper JN, McNair R, Kasama T, Gupta K, Weissberg PL, Jahnen-Dechent W, Shanahan CM: Multifunctional roles for serum protein fetuin-a in inhibition of human vascular smooth muscle cell calcification. J Am Soc Nephrol 16 : 2920 –2930, 2005
    OpenUrlAbstract/FREE Full Text
  23. ↵
    Fritsch S, Lindner V, Welsch S, Massfelder T, Grima M, Rothhut S, Barthelmebs M, Helwig JJ: Intravenous delivery of PTH/PTHrP type 1 receptor cDNA to rats decreases heart rate, blood pressure, renal tone, renin angiotensin system, and stress-induced cardiovascular responses. J Am Soc Nephrol 15 : 2588 –2600, 2004
    OpenUrlAbstract/FREE Full Text
  24. ↵
    Crass MF 3rd, Jayaseelan CL, Darter TC: Effects of parathyroid hormone on blood flow in different regional circulations. Am J Physiol 253 : R634 –R639, 1987
  25. ↵
    Kosch M, Hausberg M, Vormbrock K, Kisters K, Gabriels G, Rahn KH, Barenbrock M: Impaired flow-mediated vasodilation of the brachial artery in patients with primary hyperparathyroidism improves after parathyroidectomy. Cardiovasc Res 47 : 813 –818, 2000
    OpenUrlCrossRefPubMed
  26. ↵
    Kosch M, Hausberg M, Barenbrock M, Posadzy-Malaczynska A, Kisters K, Rahn KH: Arterial distensibility and pulse wave velocity in patients with primary hyperparathyroidism before and after parathyroidectomy. Clin Nephrol 55 : 303 –308, 2001
    OpenUrlPubMed
  27. ↵
    Weber K, Kaschig C, Erben RG: 1 Alpha-hydroxyvitamin D2 and 1 alpha-hydroxyvitamin D3 have anabolic effects on cortical bone, but induce intracortical remodeling at toxic doses in ovariectomized rats. Bone 35 : 704 –710, 2004
    OpenUrlPubMed
  28. ↵
    Coen G, Mantella D, Manni M, Balducci A, Nofroni I, Sardella D, Ballanti P, Bonucci E: 25-Hydroxyvitamin D levels and bone histomorphometry in hemodialysis renal osteodystrophy. Kidney Int 68 : 1840 –1848, 2005
    OpenUrlCrossRefPubMed
  29. ↵
    Moselewski F, Ferencik M, Achenbach S, Abbara S, Cury RC, Booth SL, Jang IK, Brady TJ, Hoffmann U: Threshold-dependent variability of coronary artery calcification measurements: Implications for contrast-enhanced multi-detector row-computed tomography. Eur J Radiol 57 : 390 –395, 2006
    OpenUrlCrossRefPubMed
  30. ↵
    Hoffmann U, Kwait DC, Handwerker J, Chan R, Lamuraglia G, Brady TJ: Vascular calcification in ex vivo carotid specimens: Precision and accuracy of measurements with multi-detector row CT. Radiology 229 : 375 –381, 2003
    OpenUrlCrossRefPubMed
  31. ↵
    Demer LL: Effect of calcification on in vivo mechanical response of rabbit arteries to balloon dilation. Circulation 83 : 2083 –2093, 1991
  32. ↵
    Li YC, Qiao G, Uskokovic M, Xiang W, Zheng W, Kong J: Vitamin D: A negative endocrine regulator of the renin-angiotensin system and blood pressure. J Steroid Biochem Mol Biol 89–90 : 387 –392, 2004
    OpenUrlCrossRef
  33. ↵
    Rey FE, Pagano PJ: The reactive adventitia: Fibroblast oxidase in vascular function. Arterioscler Thromb Vasc Biol 22 : 1962 –1971, 2002
    OpenUrlAbstract/FREE Full Text
  34. ↵
    Lyakh LA, Sanford M, Chekol S, Young HA, Roberts AB: TGF-beta and vitamin D3 utilize distinct pathways to suppress IL-12 production and modulate rapid differentiation of human monocytes into CD83+ dendritic cells. J Immunol 174 : 2061 –2070, 2005
    OpenUrlAbstract/FREE Full Text
  35. ↵
    Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R: Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: A double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 83 : 754 –759, 2006
    OpenUrlAbstract/FREE Full Text
  36. ↵
    Fahrleitner A, Dobnig H, Obernosterer A, Pilger E, Leb G, Weber K, Kudlacek S, Obermayer-Pietsch BM: Vitamin D deficiency and secondary hyperparathyroidism are common complications in patients with peripheral arterial disease. J Gen Intern Med 17 : 663 –669, 2002
    OpenUrlCrossRefPubMed
  37. ↵
    Lips P: Vitamin D physiology. Prog Biophys Mol Biol 92 : 4 –8, 2006
    OpenUrlCrossRefPubMed
  38. ↵
    Zerwekh JE, Ruml LA, Gottschalk F, Pak CY: The effects of twelve weeks of bed rest on bone histology, biochemical markers of bone turnover, and calcium homeostasis in eleven normal subjects. J Bone Miner Res 13 : 1594 –1601, 1998
    OpenUrlCrossRefPubMed
  39. ↵
    van Driel M, Koedam M, Buurman CJ, Hewison M, Chiba H, Uitterlinden AG, Pols HAP, van Leeuwen JPTM: Evidence for auto/paracrine actions of vitamin D in bone: 1alpha-hydroxylase expression and activity in human bone cells. FASEB J 20 : E1811 –E1819, 2006
    OpenUrl
  40. ↵
    Zehnder D, Bland R, Chana RS, Wheeler DC, Howie AJ, Williams MC, Stewart PM, Hewison M: Synthesis of 1,25-dihydroxyvitamin D(3) by human endothelial cells is regulated by inflammatory cytokines: A novel autocrine determinant of vascular cell adhesion. J Am Soc Nephrol 13 : 621 –629, 2002
    OpenUrlAbstract/FREE Full Text
  41. ↵
    Esteban L, Vidal M, Dusso A: 1Alpha-hydroxylase transactivation by gamma-interferon in murine macrophages requires enhanced C/EBPbeta expression and activation. J Steroid Biochem Mol Biol 89–90 : 131 –137, 2004
    OpenUrl
  42. ↵
    Lai CF, Seshadri V, Huang K, Shao JS, Cai J, Vattikuti R, Schumacher A, Loewy AP, Denhardt DT, Rittling SR, Towler DA: An osteopontin-NADPH oxidase signaling cascade promotes pro-matrix metalloproteinase 9 activation in aortic mesenchymal cells. Circ Res 98 : 1479 –1489, 2006
    OpenUrlAbstract/FREE Full Text
  43. ↵
    Kato S, Matsumoto T, Kawano H, Sato T, Takeyama K: Function of androgen receptor in gene regulations. J Steroid Biochem Mol Biol 89–90 : 627 –633, 2004
    OpenUrlCrossRef
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 18 (2)
Journal of the American Society of Nephrology
Vol. 18, Issue 2
February 2007
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
Calciotropic Hormones and Arterial Physiology: “D”-lightful Insights
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Calciotropic Hormones and Arterial Physiology: “D”-lightful Insights
Dwight A. Towler
JASN Feb 2007, 18 (2) 369-373; DOI: 10.1681/ASN.2006121367

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Calciotropic Hormones and Arterial Physiology: “D”-lightful Insights
Dwight A. Towler
JASN Feb 2007, 18 (2) 369-373; DOI: 10.1681/ASN.2006121367
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • A Novel Pathological Mechanism of Tertiary Lymphoid Structure Formation in the Renal Pelvis
  • Disarming the Old Foe. Restoring T-Cell Immune Function with mTor-Inhibitors to Tackle Cytomegalovirus Infection
  • Genome-wide Admixture Mapping of eGFR and CKD Identify European and African Ancestry-of-Origin Loci in US Hispanics/Latinos
Show more Editorials

Cited By...

  • Steroid Hormone Vitamin D: Implications for Cardiovascular Disease
  • Upregulation of Monocyte/Macrophage HGFIN (Gpnmb/Osteoactivin) Expression in End-Stage Renal Disease
  • Vitamin D and Osteogenic Differentiation in the Artery Wall
  • A Bimodal Association of Vitamin D Levels and Vascular Disease in Children on Dialysis
  • Google Scholar

Similar Articles

Related Articles

  • Mineral Metabolism and Arterial Functions in End-Stage Renal Disease: Potential Role of 25-Hydroxyvitamin D Deficiency
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals

© 2022 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire